| Literature DB >> 35966005 |
Chao Tian1, Yanyan Yang2, Bing Li3, Meixin Liu4, Xiangqin He4, Liang Zhao4, Xiaoxia Song4, Tao Yu4,5, Xian-Ming Chu1,6.
Abstract
Purpose: To explore the therapeutic mechanism of bone marrow mesenchymal stem cells derived exosomes (BMSC-Exos) for doxorubicin (DOX)-induced cardiotoxicity (DIC) and identify the long noncoding RNAs' (lncRNAs') anti-inflammation function derived by BMSC-Exos. Materials andEntities:
Keywords: doxorubicin-induced cardiotoxicity; exosomes; inflammation; transcriptome sequencing analysis
Year: 2022 PMID: 35966005 PMCID: PMC9365022 DOI: 10.2147/JIR.S358471
Source DB: PubMed Journal: J Inflamm Res ISSN: 1178-7031
The Primer Sequence for qRT-PCR
| Primer | Forward | Reverse |
|---|---|---|
| GAPDH | AAATGGTGAAGGTCGGTGTGAAC | CAACAATCTCCACTTTGCCACTG |
| IL-6 | ACAGAAGGAGTGGCTAAGGA | AGGCATAACGCACTAGGTTT |
| MSTRG.75967.15 | GCTATCCACTTCACTTTTCCA | TCTACCCAACTCCTACCTTCTC |
| MSTRG.51708.15 | CATTCTCTACCCTGCTTCGT | GCTACCTTCCTTGCTGTGTT |
| MSTRG.98097.4 | AGAGGATGAGATACACAGGCA | TCAGGAGGCTAAACAGAAGG |
| ENSMUST00000162380 | TAGTTCTTGGCGGTTTCAGT | CTCCCTCCGTCTCTCATTC |
| MSTRG.94952.19 | CAGTCATCTCTCTATCCCCTTT | CTCAGGGTAGTTCAGTGTTCC |
| MSTRG.4585.1 | GCATTAGAGAAACCAACACAGA | GAAACATAGGAGGGAACAAGAG |
| MSTRG.79460.7 | CGTGAAGACCAGAGGACAA | GTGGAGACCAGTGATACAAGG |
| MSTRG.38414.10 | CAGGAAAGATGACCAGAGGA | GGGGATGTGAAGTGTTGTG |
| MSTRG.58791.2 | TCCTTATGCTTTCTTACGATTCT | CAGTCTTTCCAGTTCTCTTGG |
| MSTRG.12633.8 | GGAGAGGCACAAAATAGAGG | AAGCAGAACCATAGGACAGC |
Figure 1Quality control of the lncRNAs. (A) Prediction of lncRNAs from four softwares. (B) Classification of lncRNAs in the samples. (C) Expression level of lncRNAs in two groups. (D) Density of lncRNAs in two groups. (E) The cumulative distribution of conservative scores for lncRNA and mRNA. (F) Conservative score cumulative distribution. (G) Conservative score probability density curve.
Figure 2The difference expression of lncRNAs analysis. (A) The correlation analysis between the DOX group and BEC group. (B) The volcano plot of up- and downregulated lncRNAs in BEC group compared with DOX group. (C) The hierarchical clustering and difference of lncRNAs between the two groups.
The Top 10 ElncRNAs in the BEC Group
| #ID | Gene Symbol | FDR | log2FC |
|---|---|---|---|
| MSTRG.75967.15 | MSTRG.75967.15 | 5.42443667337116e-13 | 11.4600038610119 |
| MSTRG.51708.15 | MSTRG.51708.15 | 5.8756853381905e-13 | 13.1167967798597 |
| MSTRG.98097.4 | MSTRG.98097.4 | 3.23018583900885e-11 | 11.182354925168 |
| ENSMUST00000162380 | 4933413C19Rik-201 | 4.75803514666033e-11 | 10.7524877343357 |
| MSTRG.94952.19 | MSTRG.94952.19 | 7.80723842820196e-11 | 10.2750351208207 |
| MSTRG.4585.1 | MSTRG.4585.1 | 1.23559402741018e-10 | 10.1592494783464 |
| MSTRG.79460.7 | MSTRG.79460.7 | 1.81601942028659e-10 | 11.6374422495268 |
| MSTRG.38414.10 | MSTRG.38414.10 | 5.11526492667872e-10 | 9.9517968399127 |
| MSTRG.58791.2 | MSTRG.58791.2 | 5.72877434917132e-10 | 9.69214161606425 |
| MSTRG.12633.8 | MSTRG.12633.8 | 6.37378605363441e-10 | 9.565391746026 |
Figure 3The GO enrichment analysis of cis_targets of ElncRNAs. (A) Enrichment analysis of biological process (BP) of cis_targets. (B) Enrichment analysis of cellular component (CC) of cis_targets. (C) Enrichment analysis of molecular function (MF) of cis_targets.
Figure 4The KEGG analysis of cis_targets of ElncRNAs. (A) The enrichment of pathways of cis_targets. (B) The whole outlook of enriched pathways, including cellular process, environmental processing, genetic information processing, human diseases and original systems, of cis_targets.
Figure 5The crucial signaling pathways. (A) The chemokine signaling pathway. (B) The cellular senescence signaling pathway. (C) The mTOR signaling pathway. (D) The p53 signaling pathway.
Figure 6The cell verification experiments. (A) The CCK-8 assay. (B) The ROS experiment (The scale bar is 100μm). (C) The relative expression of IL-6 in each group. (D) The relative expression of MSTRG.75967.15 in each group. (E) The relative expression of MSTRG.51708.15 in each group. (F) The relative expression of MSTRG.98097.4 in each group. (G) The relative expression of ENSMUST00000162380 in each group. (H) The relative expression of MSTRG.94952.19 in each group. (I) The relative expression of MSTRG.4585.1 in each group. (J) The relative expression of MSTRG.79460.7 in each group. (K) The relative expression of MSTRG.38414.10 in each group. (L) The relative expression of MSTRG.58791.2 in each group. (M) The relative expression of MSTRG.12633.8 in each group. (ns, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.).
Figure 7The lncRNA-mRNA network between two candidate lncRNAs and their target genes. (A) The common target genes of MSTRG.58791.2 and MSTRG.98097.4. (B) The network and core genes involving in DIC.
The Target Genes of MSTRG.58791.2 and MSTRG.98097.4
| LncRNA | Target Genes | Common Target Genes |
|---|---|---|
| MSTRG.58791.2 | Slfn4, Pdgfb, Hk2, Cd52, Ccl3, Acp5, Il7r, Ndrg1, Mmp8, Atp1a2, Rarres2, Kcnq1, Cox4i2, Cybb, Ncf1, Cd274, Aldoc, Ccl4, Adarb1, Pfkl, Tppp, Fyb, Cd86, Wnt10b, Ache, Tpi1, Slc5a7, Vegfa, Sik1, C3, Slc15a3, Slc16a3, Gpr35, Slamf9, Traf1, Psd4, Il1rn, Il1a, Sema4a, Car9, Pramef12, Slc10a6, Clec5a, Plbd1, Coro1a, Itgal, Arhgap4, Egln1, Oas3, Nlrp3, Rac2, Rasd2, Unc13a, Igsf6, Egln3, Abhd18, Tgm2, Prdm1, Metrnl, Dock3, Fmo2, Milr1, Atp1a3, Atp1b2, Kif21b, Efhc1, Trem1, Dusp15, Mrap2, Ccrl2, Smtnl2, Mmp10, Tmem196, C5ar1, Tifab, Nlrp10, Oprd1, Rtn4rl2, Spn, Cysltr1, Prelid2, Osm, Ldha, Cenpm, Gm8225, Selenbp1, Tmem35b, Tigit, Csf2rb, Cpne1, Gal3st4, Slfn1, Tmem182, Bcl2a1b, Bcl2a1d, Bcl2a1a, Gm43720 | Pdgfb, Hk2, Cd52, Ccl3, Acp5, Il7r, Ndrg1, Mmp8, Atp1a2, Rarres2, Kcnq1, Cox4i2, Cybb, Ncf1, Aldoc, Ccl4, Adarb1, Pfkl, Tppp, Fyb, Cd86, Wnt10b, Ache, Tpi1, Slc5a7, Vegfa, Sik1, C3, Slc15a3, Slc16a3, Gpr35, Slamf9, Psd4, Il1rn, Sema4a, Car9, Pramef12, Slc10a6, Plbd1, Itgal, Arhgap4, Egln1, Oas3, Nlrp3, Rac2, Rasd2, Unc13a, Igsf6, Egln3, Abhd18, Tgm2, Prdm1, Metrnl, Dock3, Fmo2, Milr1, Atp1a3, Atp1b2, Kif21b, Efhc1, Trem1, Dusp15, Mrap2, Ccrl2, Smtnl2, Mmp10, Tmem196, C5ar1, Tifab, Nlrp10, Oprd1, Rtn4rl2, Spn, Cysltr1, Prelid2, Osm, Ldha, Cenpm, Gm8225, Selenbp1, Tmem35b, Tigit, Csf2rb, Cpne1, Gal3st4, Slfn1, Tmem182, Bcl2a1b, Bcl2a1d, Bcl2a1a, Gm43720 |
| MSTRG.98097.4 | Pdgfb, Hk2, Cd52, Ccl3, Acp5, Tbc1d8, Cp, Il7r, Cd33, Pgf, Slc2a9, Ndrg1, Mmp8, Pdk1, Atp1a2, Rarres2, Kcnq1, Cox4i2, Hyal1, Exoc3l2, Aldh1a3, Cybb, Ncf1, Ift27, Aldoc, Stac2, Myh11, P4ha2, Ccl4, Plod1, Arg1, Adarb1, Pfkl, Fstl3, Adcy2, Tppp, Thbs4, Ero1l, Ednrb, Fyb, Efs, Tgm1, Gtse1, Samsn1, Cd86, Wnt10b, Bsg, Ache, Tpi1, Slc5a7, Vegfa, Sik1, C3, Lvrn, Lox, Slc15a3, Cst6, Vldlr, Slc16a3, Adam8, Alox5, Gpr35, Slamf9, Psd4, Il1rn, Prrg4, Gss, Wisp2, Efna3, Sema4a, Car9, Ak4, Pramef12, Slc2a1, Sytl1, Ppp2r2c, Slc10a6, 1700003E16Rik, Plbd1, Itgal, Mmp15, Egln1, St14, Pdgfd, 4833427G06Rik, Trf, Nlrp3, Rac2, Dpyd, Rasd2, Celf5, Igsf6, Egln3, Prtg, Slc18a1, Pafah2, Tgm2, Zfp365, Pln, Metrnl, Dock3, Maob, Thbs1, Fmo2, Nxph4, Milr1, Cmtm5, Atp1a3, Atp1b2, Kif21b, Efhc1, Trem1, AA986860, Dusp15, Apobr, Mrap2, Foxf1, Mmp3, Ccrl2, Kcnj4, S1pr1, Smtnl2, Adamts6, Nexmif, Dusp28, Mmp10, Stbd1, Palm3, Tmem196, Tmem229a, Zbtb8b, C5ar1, Scn3b, Tifab, Nlrp10, Ppp1r3g, Oprd1, Rtn4rl2, Ankrd37, Ppp1r36, Cysltr1, Gpr141, Arhgap20, Cthrc1, Triqk, Prelid2, Usp13, Lmcd1, Nkx2-9, Osm, Pgk1, Ldha, Eno1, Hhip, Cenpm, Gm8225, Gm4841, Trp53i11, Selenbp1, Tmem35b, Tigit, Csf2rb, Fam196a, C5ar2, Cpne1, Pak6, Gal3st4, Slfn1, Naip2, Bcl2a1b, Sec14l5, Gm7942, Bcl2a1d, Bcl2a1a, Gm43720, Zscan4-ps1 |
Figure 8The verification experiments in vivo. (A) Exosomes photographed by transmission electron microscopy (TEM). (B) The nanoparticle diameter identified by NTA. (C) The schematic design of animal experiment. (D) The survival rate of different groups (p<0.05). (E) The Sirius Red Staining. (F) The relative expression of IL-1β. (G) The relative expression of IL-6 in each group. (H) The relative expression of MSTRG.58791.2 in each group. (I) The relative expression of MSTRG.98097.4 in each group. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Figure 9The whole process of the study.